Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: A multicentre clinical trial

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 8, 2011, Pages 1847-1852

  Liou, Jyh Ming ^a,b   Chen, Chieh Chang ^a   Chen, Mei Jyh ^a   Chang, Chi Yang ^c   Fang, Yu Jen ^a   Lee, Ji Yuh ^a   Sheng, Wang Huei ^a   Wang, Hsiu Po ^a   Wu, Ming Shiang ^a,d   Lin, Jaw Town ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c E DA HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

CYP2C19; gyrA; Metronidazole; Rescue; Resistance

Indexed keywords

AMOXICILLIN; CARBON 13; CLARITHROMYCIN; CYTOCHROME P450 2C19; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ESOMEPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENOME; BLOATING; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DIZZINESS; DNA POLYMORPHISM; DRUG MEGADOSE; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; GENE MUTATION; GENOTYPE; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; RASH; SEQUENTIAL THERAPY; TASTE DISORDER; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT WITHDRAWAL; UREA BREATH TEST; VOMITING;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; BREATH TESTS; DNA GYRASE; DRUG MONITORING; FEMALE; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OFLOXACIN; OMEPRAZOLE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; UREA;

EID: 79960458098     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr217     Document Type: Article

References (35)

1. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet 2009; 374: 1449-61.
2. Fletcher EH, Johnston DE, Fisher CR et al. Systematic review: Helicobacter pylori and upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther 2010; 32: 831-9.
3. Talley NJ, Fock KM, Moayyedi P. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol 2008; 103: 510-4.
4. Wu CY, Kuo KN, Wu MS et al. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009; 137: 1641-8.e1-2.
5. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2007; 56: 772-81.
6. Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25.
7. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-53.
8. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008; 148: 923-31.
9. Vaira D, Zullo A, Vakil N et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007; 146: 556-63.
10. Zullo A, De Francesco V, Hassan C et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007; 56: 1353-7.
11. Gatta L, Vakil N, Leandro G et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104: 3069-79.
12. Sirimontaporn N, Thong-Ngam D, Tumwasorn S et al. Ten-day sequential therapy of Helicobacter pylori infection in Thailand. Am J Gastroenterol 2010; 105: 1071-5.
13. Wu DC, Hsu PI, Wu JY et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol 2010; 8: 36-41.e1.
14. Nista EC, Candelli M, Zocco MA et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 2006; 101: 1985-90.
15. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35-44.
16. Saad RJ, Schoenfeld P, Kim HM et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006; 101: 488-96.
17. Gisbert JP, Bermejo F, Castro-Fernández M et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 2008; 103: 71-6.
18. Liou JM, Lin JT, Chang CY et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut 2010; 59: 572-8.
19. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28: 868-77.
20. Graham DY, Abudayyeh S, El-Zimaity HM et al. Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 24: 845-50.
21. Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: 280-322.
22. Dubreuil L, Devos J, Beerens H et al. In vitro activity of an ofloxacin-metronidazole combination against anaerobic bacteria. Kinetics of the action of metronidazole against Bacteroides fragilis. Pathol Biol (Paris) 1988; 36: 488-92.
23. Neu HC, Chin NX. In vitro activity of fleroxacin in combination with other antimicrobial agents. Am J Med 1993; 94: 9S-16S.
24. Liou JM, Chang CY, Sheng WH et al. Genotype resistance determined on strains correlates with susceptibility test and treatment outcomes after levofloxacin and clarithromycin based therapies for Helicobacter pylori. Antimicrob Agents Chemother 2011; 55: 1123-9.
25. Lee YC, Lin JT, Wang HP et al. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. J Gastroenterol Hepatol 2007; 22: 1286-92.
26. Svensson M, Nilsson LE, Ström M et al. Pharmacodynamic effects of nitroimidazoles alone and in combination with clarithromycin on Helicobacter pylori. Antimicrob Agents Chemother 2002; 46: 2244-8.
27. Romano M, Cuomo A, Gravina AG et al. Empirical levofloxacincontaining versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010; 59: 1465-70.
28. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M et al. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010; 31: 1077-84.
29. Aydin A, Oruc N, Turan I et al. The modified sequential treatment regimen containing levofloxacin for Helicobacter pylori eradication in Turkey. Helicobacter 2009; 14: 520-4.
30. Krystallis C, Kamberoglou D, Pistiolas D et al. A new second-line sequential regimen for Helicobacter pylori eradication based on levofloxacin: a pilot study. Dig Dis Sci 2010; 55: 3630-1.
31. Erçin CN, Uygun A, Toros AB et al. Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. Turk J Gastroenterol 2010; 21: 12-6.
32. Kuo CH, Hu HM, Kuo FC et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 2009; 63: 1017-24.
33. Poon SK, Lai CH, Chang CS et al. Prevalence of antimicrobial resistance in Helicobacter pylori isolates in Taiwan in relation to consumption of antimicrobial agents. Int J Antimicrob Agents 2009; 34: 162-5.
34. Romano M, Iovene MR, Russo MI et al. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J Clin Pathol 2008; 61: 1112-5.
35. Marais A, Monteiro L, Occhialini A et al. Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens. Gut 1999; 44: 463-7.